News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
551,651 Results
Type
Article (46607)
Company Profile (119)
Press Release (504914)
Multimedia
Podcasts (143)
Webinars (19)
Section
Business (145740)
Career Advice (2419)
Deals (28114)
Drug Delivery (141)
Drug Development (68516)
Employer Resources (158)
FDA (15978)
Job Trends (12062)
News (265549)
Policy (29907)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2316)
Academic (1)
Accelerated approval (36)
Adcomms (36)
Allergies (137)
Alliances (36151)
ALS (163)
Alzheimer's disease (1712)
Antibody-drug conjugate (ADC) (317)
Approvals (16122)
Artificial intelligence (501)
Autoimmune disease (165)
Automation (33)
Bankruptcy (312)
Best Places to Work (9192)
BIOSECURE Act (23)
Biosimilars (192)
Biotechnology (69)
Bladder cancer (157)
Brain cancer (54)
Breast cancer (589)
Cancer (4553)
Cardiovascular disease (411)
Career advice (2046)
Career pathing (39)
CAR-T (260)
CDC (60)
Celiac Disease (1)
Cell therapy (724)
Cervical cancer (35)
Clinical research (58868)
Collaboration (1492)
Company closure (4)
Compensation (1163)
Complete response letters (76)
COVID-19 (2720)
CRISPR (90)
C-suite (795)
Cystic fibrosis (141)
Data (5818)
Decentralized trials (2)
Denatured (32)
Depression (149)
Diabetes (481)
Diagnostics (5544)
Digital health (38)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (221)
Drug pricing (221)
Drug shortages (33)
Duchenne muscular dystrophy (239)
Earnings (62332)
Editorial (67)
Employer branding (20)
Employer resources (142)
Events (81904)
Executive appointments (899)
FDA (19062)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (20)
Funding (1276)
Gene editing (196)
Generative AI (43)
Gene therapy (610)
GLP-1 (1067)
Government (4198)
Grass and pollen (8)
Guidances (376)
Healthcare (14885)
HIV (61)
Huntington's disease (50)
IgA nephropathy (86)
Immunology and inflammation (291)
Immuno-oncology (59)
Indications (102)
Infectious disease (2985)
Inflammatory bowel disease (186)
Inflation Reduction Act (14)
Influenza (109)
Intellectual property (240)
Interviews (453)
IPO (14134)
IRA (58)
Job creations (3173)
Job search strategy (1672)
JPM (67)
Kidney cancer (17)
Labor market (84)
Layoffs (619)
Leadership (40)
Legal (7016)
Liver cancer (90)
Longevity (12)
Lung cancer (603)
Lymphoma (356)
Machine learning (40)
Management (52)
Manufacturing (739)
MASH (169)
Medical device (11584)
Medtech (11629)
Mergers & acquisitions (14978)
Metabolic disorders (1320)
Multiple sclerosis (147)
NASH (22)
Neurodegenerative disease (324)
Neuropsychiatric disorders (98)
Neuroscience (2921)
Neurotech (1)
NextGen: Class of 2026 (4996)
Non-profit (3194)
Now hiring (31)
Obesity (663)
Opinion (279)
Ovarian cancer (153)
Pain (189)
Pancreatic cancer (220)
Parkinson's disease (276)
Partnered (26)
Patents (481)
Patient recruitment (464)
Peanut (54)
People (44218)
Pharmaceutical (33)
Pharmacy benefit managers (32)
Phase 1 (17661)
Phase 2 (25471)
Phase 3 (20870)
Pipeline (5075)
Policy (335)
Postmarket research (2207)
Preclinical (7144)
Press Release (28)
Prostate cancer (240)
Psychedelics (56)
Radiopharmaceuticals (247)
Rare diseases (889)
Real estate (4303)
Recruiting (65)
Regulatory (23208)
Reports (41)
Research institute (2117)
Resumes & cover letters (404)
Rett syndrome (27)
RNA editing (16)
RSV (74)
Schizophrenia (153)
Series A (216)
Series B (177)
Service/supplier (8)
Sickle cell disease (97)
Special edition (26)
Spinal muscular atrophy (139)
Sponsored (47)
Startups (2787)
State (1)
Stomach cancer (20)
Supply chain (105)
Tariffs (101)
The Weekly (110)
Vaccines (1102)
Venture capital (96)
Weight loss (467)
Women's health (75)
Worklife (22)
Date
Today (128)
Last 7 days (524)
Last 30 days (2026)
Last 365 days (28190)
2026 (3383)
2025 (28397)
2024 (31399)
2023 (34982)
2022 (45060)
2021 (48498)
2020 (45513)
2019 (36211)
2018 (27400)
2017 (27806)
2016 (25807)
2015 (27975)
2014 (21779)
2013 (17795)
2012 (18966)
2011 (19384)
2010 (17518)
Location
Africa (686)
Alabama (66)
Alaska (6)
Arizona (231)
Arkansas (10)
Asia (32361)
Australia (5666)
California (10454)
Canada (2519)
China (918)
Colorado (409)
Connecticut (463)
Delaware (306)
Europe (79030)
Florida (1584)
Georgia (319)
Hawaii (4)
Idaho (39)
Illinois (744)
India (55)
Indiana (426)
Iowa (22)
Japan (409)
Kansas (106)
Kentucky (25)
Louisiana (19)
Maine (73)
Maryland (1290)
Massachusetts (7563)
Michigan (268)
Minnesota (555)
Mississippi (5)
Missouri (118)
Montana (12)
Nebraska (22)
Nevada (111)
New Hampshire (60)
New Jersey (2815)
New Mexico (15)
New York (2706)
North Carolina (1354)
North Dakota (7)
Northern California (5194)
Ohio (280)
Oklahoma (15)
Oregon (34)
Pennsylvania (2008)
Puerto Rico (18)
Rhode Island (32)
South America (1045)
South Carolina (64)
South Dakota (1)
Southern California (4064)
Tennessee (151)
Texas (1556)
United States (36558)
Utah (264)
Virginia (244)
Washington D.C. (73)
Washington State (831)
West Virginia (4)
Wisconsin (111)
Wyoming (1)
551,651 Results for "lfb s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
New Data Underscoring Ability of Leapfrog Bio’s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal
January 12, 2026
·
4 min read
Alzheimer’s disease
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
February 9, 2026
·
4 min read
·
Annalee Armstrong
BioMidwest
LFB Plasma Joins Plasma Protein Therapeutics Association (PPTA)
LFB Plasma, a US-based plasma collection company and subsidiary of the LFB Group, a leading European company providing plasma-derived products to healthcare professionals, announces joining the Plasma Protein Therapeutics Association.
September 9, 2022
·
2 min read
Alzheimer’s disease
In Novo’s GLP-1 Failure, Alzheimer’s Space Spies a Combination Opportunity
Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry experts see potential in more testing of GLP-1s for the neurodegenerative disease, particularly in a combination approach.
January 2, 2026
·
5 min read
·
Annalee Armstrong
Alzheimer’s disease
Novartis Makes $1.5B+ Alzheimer’s Play With China’s SciNeuro
The deal will see Novartis gain global rights over SciNeuro’s potentially disease-modifying anti-amyloid antibody, which leverages the latter’s proprietary shuttle platform to allow delivery into the brain.
January 12, 2026
·
2 min read
·
Tristan Manalac
Complete response letters
FDA Rejects Disc’s Rare Blood Disease Drug Amid Reports of Prasad’s Skepticism
The FDA in October 2025 granted bitopertin its Commissioner’s National Priority Voucher but after a shortened review time has decided the data did not support regulatory approval for treating erythropoietic protoporphyria.
February 16, 2026
·
3 min read
·
Tristan Manalac
Vaccines
Flu Vaccine Rejection Imperils Moderna’s Breakeven Plans
Moderna’s mRNA-1010 was expected to contribute $1 billion to the company’s coffers by 2028. That plan is now out the window after the FDA refused to even look at the application.
February 12, 2026
·
4 min read
·
Dan Samorodnitsky
Parkinson’s disease
AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression
In a first for the Parkinson’s field, AC Immune’s immunotherapy has stabilized key biomarkers that suggest an effect on the disease’s course.
December 11, 2025
·
1 min read
·
Annalee Armstrong
Collaboration
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy
Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with insitro, Orbital and more are building the future.
January 12, 2026
·
3 min read
·
Annalee Armstrong
LFB Announces the Approval of CEVENFACTA® (eptacog beta) in the European Union
LFB today announced that the European Medicines Agency (EMA) has granted on July 15th a Marketing Authorisation for CEVENFACTA® (eptacog beta), as the first new bypassing agent in over 20 years.
July 25, 2022
·
5 min read
1 of 55,166
Next
